These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37496216)

  • 1. [Therapeutic Strategies Targeting HER2 for Gastric Cancer].
    Baba K; Boku N
    Gan To Kagaku Ryoho; 2023 Jul; 50(7):756-762. PubMed ID: 37496216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer.
    Ishii T; Shitara K
    Expert Rev Anticancer Ther; 2021 Nov; 21(11):1193-1201. PubMed ID: 34543577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging HER2-directed therapeutic agents for gastric cancer in early phase clinical trials.
    Lote H; Chau I
    Expert Opin Investig Drugs; 2022 Jan; 31(1):59-78. PubMed ID: 35034511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An overview of the preclinical discovery and development of trastuzumab deruxtecan: a novel gastric cancer therapeutic.
    Kalmuk J; Rinder D; Heltzel C; Lockhart AC
    Expert Opin Drug Discov; 2022 May; 17(5):427-436. PubMed ID: 35426752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis.
    Wang HB; Liao XF; Zhang J
    Medicine (Baltimore); 2017 Nov; 96(44):e8437. PubMed ID: 29095284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
    Van Cutsem E; Bang YJ; Feng-Yi F; Xu JM; Lee KW; Jiao SC; Chong JL; López-Sanchez RI; Price T; Gladkov O; Stoss O; Hill J; Ng V; Lehle M; Thomas M; Kiermaier A; Rüschoff J
    Gastric Cancer; 2015 Jul; 18(3):476-84. PubMed ID: 25038874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer.
    Lordick F
    Future Oncol; 2011 Feb; 7(2):187-99. PubMed ID: 21345138
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 testing in gastric cancer.
    Albarello L; Pecciarini L; Doglioni C
    Adv Anat Pathol; 2011 Jan; 18(1):53-9. PubMed ID: 21169738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2 Targeting in Esophagogastric Cancer: Redefining the Landscape and Breaking Barriers.
    Cytryn SL; Janjigian YY
    J Natl Compr Canc Netw; 2023 Apr; 21(4):423-429. PubMed ID: 37015333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Bang YJ; Van Cutsem E; Feyereislova A; Chung HC; Shen L; Sawaki A; Lordick F; Ohtsu A; Omuro Y; Satoh T; Aprile G; Kulikov E; Hill J; Lehle M; Rüschoff J; Kang YK;
    Lancet; 2010 Aug; 376(9742):687-97. PubMed ID: 20728210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting HER2 in metastatic gastroesophageal adenocarcinomas: What is new?
    Coutzac C; Funk-Debleds P; Cattey-Javouhey A; Desseigne F; Guibert P; Marolleau P; Rochefort P; de la Fouchardière C
    Bull Cancer; 2023 May; 110(5):552-559. PubMed ID: 36229267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
    Wagner AD; Grabsch HI; Mauer M; Marreaud S; Caballero C; Thuss-Patience P; Mueller L; Elme A; Moehler MH; Martens U; Kang YK; Rha SY; Cats A; Tokunaga M; Lordick F
    BMC Cancer; 2019 May; 19(1):494. PubMed ID: 31126258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective.
    Aoki M; Iwasa S; Boku N
    Gastric Cancer; 2021 May; 24(3):567-576. PubMed ID: 33646464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies.
    Pous A; Notario L; Hierro C; Layos L; Bugés C
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and future perspectives in HER2 positive advanced gastric cancer.
    Roviello G; Catalano M; Iannone LF; Marano L; Brugia M; Rossi G; Aprile G; Antonuzzo L
    Clin Transl Oncol; 2022 Jun; 24(6):981-996. PubMed ID: 35091998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment.
    An E; Ock CY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Liao WL; Cecchi F; Blackler A; Thyparambil S; Kim WH; Burrows J; Hembrough T; Catenacci DVT; Oh DY; Bang YJ
    Ann Oncol; 2017 Jan; 28(1):110-115. PubMed ID: 27687309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer.
    Ko BK; Lee SY; Lee YH; Hwang IS; Persson H; Rockberg J; Borrebaeck C; Park D; Kim KT; Uhlen M; Lee JS
    Mol Oncol; 2015 Feb; 9(2):398-408. PubMed ID: 25306393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Epidermal Growth Factor Receptor 2 (HER2) in Advanced Gastric Cancer: Current Knowledge and Future Perspectives.
    Palle J; Rochand A; Pernot S; Gallois C; Taïeb J; Zaanan A
    Drugs; 2020 Mar; 80(4):401-415. PubMed ID: 32077003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
    Mishima S; Shitara K
    Expert Opin Biol Ther; 2021 Jul; 21(7):825-830. PubMed ID: 33798395
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer.
    Mezynski MJ; Farrelly AM; Cremona M; Carr A; Morgan C; Workman J; Armstrong P; McAuley J; Madden S; Fay J; Sheehan KM; Kay EW; Holohan C; Elamin Y; Rafee S; Morris PG; Breathnach O; Grogan L; Hennessy BT; Toomey S
    J Transl Med; 2021 May; 19(1):184. PubMed ID: 33933113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.